Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus

Journal of the American Heart Association

Volumn 5, Issue 6, 2016, Pages

  van der Leeuw, Joep ^a   Beulens, Joline W J ^b   van Dieren, Susan ^b,c   Schalkwijk, Casper G ^a,d,e   Glatz, Jan F C ^d   Hofker, Marten H ^e   Monique Verschuren, W M ^b,f   Boer, Jolanda M A ^g   van der Graaf, Yolanda ^b   Visseren, Frank L J ^a   Peelen, Linda M ^b   van der Schouw, Yvonne T ^b  

^a Department of Vascular Medicine ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Biomarker; Cardiovascular disease prevention; Cardiovascular disease risk factors; Risk stratification

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR; FMS LIKE TYROSINE KINASE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; INTERSTITIAL COLLAGENASE; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; PADGEM PROTEIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SERUM AMYLOID A; STROMELYSIN; THROMBOMODULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; MMP3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; BLOOD; DIABETIC ANGIOPATHY; EVALUATION STUDY; METABOLISM; MIDDLE AGED; NETHERLANDS; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84991522515     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.003048     Document Type: Article

References (39)

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137-149.
2. Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CDA, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
4. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, Ratner RE, Resnick HE, Devereux RB. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391-397.
5. Paynter NP, Mazer NA, Pradhan AD, Gaziano JM, Ridker PM, Cook NR. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. Arch Intern Med. 2011;171:1712-1718.
6. van Dieren S, Beulens JWJ, Kengne AP, Peelen LM, Rutten GEHM, Woodward M, van der Schouw YT, Moons KGM. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart. 2012;98:360-369.
7. Van der Leeuw J, Van Dieren S, Beulens JWJ, Boeing H, Spijkerman A, Van der Graaf Y, Van der A DL, Nothlings U, Visseren FLJ, Rutten GEHM, Moons KGM, Van der Schouw YT, Peelen LM. The validation of cardiovascular risk scores for patients with type 2 diabetes. Heart. 2015;101:222-229.
8. Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157:160-168.
9. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120:2177-2187.
10. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002;252:283-294.
11. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999;15:773-781.
12. Beulens JWJ, Monninkhof EM, Monique Verschuren WM, van der Schouw YT, Smit J, Ocke MC, Jansen EHJM, van Dieren S, Grobbee DE, Peeters PHM, Bueno-de-Mesquita HB. Cohort profile: the EPIC-NL study. Int J Epidemiol. 2010;39:1170-1178.
13. Sluijs I, van der A DL, Beulens JWJ, Spijkerman AMW, Ros MM, Grobbee DE, van der Schouw YT. Ascertainment and verification of diabetes in the EPIC-NL study. Neth J Med. 2010;68:333-339.
14. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46:136-140.
15. Merry AHH, Boer JMA, Schouten LJ, Feskens EJM, Verschuren WMM, Gorgels APM, van der Brandt PA. Validity of coronary heart diseases and heart failure based on hospital discharge and mortality data in the Netherlands using the cardiovascular registry Maastricht cohort study. Eur J Epidemiol. 2009;24:237-247.
16. Onland-Moret NC, van der A DL, van der Schouw YT, Buschers W, Elias SG, van Gils CH, Koerselman J, Roest M, Grobbee DE, Peeters PHM. Analysis of casecohort data: a comparison of different methods. J Clin Epidemiol. 2007;60:350-355.
17. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671-679.
18. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
19. Leening MJG, Vedder MM, Witteman JCM, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies. Ann Intern Med. 2014;160:122-131.
20. van Buuren S. Flexible Imputation of Missing Data. Boca Raton, FL, United States: Taylor and Francis Ltd; 2012.
21. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928-935.
22. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
23. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med. 2014;2800:1-8.
24. Gerstein HC, Paré G, McQueen MJ, Haenel H, Lee SF, Pogue J, Maggioni AP, Yusuf S, Hess S; Investigators OT. Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation. 2015;132:2297-2304.
25. Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J. 2013;34:443-450.
26. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, Jun M, Neal B, Zoungas S, Poulter N, Mancia G, Williams B, Sattar N, Woodward M. The relative and combined ability of high-sensitivity cardiac troponin T and Nterminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37:295-303.
27. Davies MJ. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation. 1998;97:2382-2383.
28. Wang J, Xu D, Wu X, Zhou C, Wang H, Guo Y, Cao K. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart. 2011;97:1542-1546.
29. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005;35:537-545.
30. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055-1061.
31. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Geroldi D. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006;27:802-807.
32. Gordin D, Forsblom C, Panduru NM, Thomas MC, Bjerre M, Soro-Paavonen A, Tolonen N, Sandholm N, Flyvbjerg A, Harjutsalo V, Groop P-H. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2014;37:2593-2600.
33. Looker HC, Colombo M, Agakov F, Zeller T, Groop L, Thorand B, Palmer CN, Hamsten A, de Faire U, Nogoceke E, Livingstone SJ, Salomaa V, Leander K, Barbarini N, Bellazzi R, van Zuydam N, McKeigue PM, Colhoun HM. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia. 2015;58:1363-1371.
34. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJL, Barr ELM, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FGR, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CDA, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GDO, Wareham NJ, Khaw K-T, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320.
35. Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FLJ. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007;154:750.e751-757.
36. Sook Lee E, Park S-S, Kim E, Sook Yoon Y, Ahn H-Y, Park C-Y, Ho Yun Y, Woo Oh S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013;42:1029-1039.
37. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1):S1-S98.
38. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen M-R, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Hoes AW, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013;34:3035-3087.
39. Marshall A, Altman DG, Holder RL. Comparison of imputation methods for handling missing covariate data when fitting a cox proportional hazards model: a resampling study. BMC Med Res Methodol. 2010;10:112.